STOCK TITAN

SeaStar Medical (ICU) okays 1-for-10 reverse split and cuts authorized shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

SeaStar Medical Holding Corporation is implementing a 1-for-10 reverse stock split of its common stock, approved at a special shareholder meeting and effective as of 12:01 a.m. Eastern on January 2, 2026. Every 10 existing shares will be combined into one new share, with no fractional shares issued; any fractional positions will be rounded up to the next whole share. All outstanding stock options and warrants will be proportionally adjusted, and the stock will continue trading on the Nasdaq Capital Market under the symbol ICU on a split-adjusted basis starting January 2, 2026. Immediately after the split, there will be approximately 3.8 million shares of common stock outstanding. Shareholders also approved reducing authorized common shares by 25,000,000 to a total of 425,000,000.

Positive

  • None.

Negative

  • None.

Insights

SeaStar restructures its equity via 1-for-10 reverse split and trims authorized shares.

SeaStar Medical Holding Corporation received shareholder approval for a 1-for-10 reverse stock split, effective as of January 2, 2026. This combines every 10 issued and outstanding common shares into one, leaving approximately 3.8 million common shares outstanding immediately after the change, while keeping the par value at $0.0001 per share. All existing stock options and warrants will be adjusted proportionally so that their economic terms remain consistent on a split-adjusted basis.

No fractional shares will be issued; instead, any fractional entitlements will be rounded up to the next whole share, slightly increasing the post-split share count compared with a strict 10-to-1 ratio. The company’s common stock will continue to trade on the Nasdaq Capital Market under the ticker ICU on a split-adjusted basis starting January 2, 2026. Shareholders also approved an amendment to reduce authorized common shares by 25,000,000 to 425,000,000, modestly constraining potential future issuance without affecting current outstanding shares.

false 0001831868 0001831868 2025-12-18 2025-12-18 0001831868 icu:CommonStockCustomMember 2025-12-18 2025-12-18 0001831868 icu:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockFor1150PerShareCustomMember 2025-12-18 2025-12-18
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 18, 2025
 

 
SeaStar Medical Holding Corporation
 
(Exact name of Registrant as Specified in Its Charter)
 

 
Delaware
001-39927
85-3681132
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
3513 Brighton Blvd, Suite 410
 
Denver, Colorado
 
80216
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrants Telephone Number, Including Area Code: 844 427-8100
 
(Former Name or Former Address, if Changed Since Last Report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange on which registered
Common Stock par value $0.0001 per share
 
ICU
 
The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share
 
ICUCW
 
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
 
 

 
 
Item 3.03 - Material Modification to Rights of Security Holders
 
On December 18, 2025, SeaStar Medical Holding Corporation (“the Company”) held a special meeting of the shareholders (the "Special Meeting") during which the stockholders approved a 1-for-10 reverse stock split of the Company's common stock (the "Reverse Split"). The Board of Directors of the Company previously approved the Reverse Split subject to stockholder approval. The Reverse Split will be effective as of 12:01 AM Eastern Standard Time on January 2, 2026, and the Company's shares of common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on January 2, 2026 under the same symbol "ICU". All stock options and warrants of the Company outstanding immediately prior to the Reverse Split will be proportionally adjusted.
 
As a result of the Reverse Split, every 10 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.0001 per share. The Company will not issue any fractional shares in connection with the Reverse Split. Instead, the number of shares will be rounded up to the next whole number. The Reverse Split will not modify the rights or preferences of the common stock. Immediately after the Reverse Split becomes effective, there will be approximately 3.8 million shares of common stock issued and outstanding.
 
The Company has appointed its transfer agent, Continental Stock Transfer and Trust Company, Inc., to act as exchange agent for the reverse stock split. Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the Reverse Split and will not be required to take further action in connection with the Reverse Split, subject to brokers' particular processes.
 
Item 5.07 Submission of Matters to a Vote of Security Holders.
 
The Special Meeting was held virtually on December 18, 2025 at 10:00 a.m., Mountain Time. The following proposals were approved by the stockholders, each by the votes set forth below:
 
Proposal 1. To approve an Amendment to our Third Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") to effect a reverse stock split of the Company's Common Stock at a ratio of 1-for-10, without reducing the authorized number of shares of the Common Stock, to be effected in the sole discretion of the Board at any time within one year of the date of the Special Meeting without further approval or authorization of stockholders (the "Reverse Stock Split Proposal") 
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
16,454,058   5,600,251   124,514  
 
 
Proposal 2. To approve an Amendment to our Certificate of Incorporation to reduce the number of authorized shares of common stock by 25,000,000 to 425,000,000 (the "Authorized Share Proposal")
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
18,617,183   3,465,583   96,057  
 
Proposal 3. To approve a proposal to adjourn or postpone the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal or Authorized Share Proposal
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
17,092,841   4,844,571   241,411  
 
 
 
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
SeaStar Medical Holding Corporation
 
   
By:
/s/ Eric Schlorff
Date:
December 18, 2025
Name:
Eric Schlorff
   
Title:
Chief Executive Officer
 
 

FAQ

What reverse stock split did SeaStar Medical (ICU) approve?

SeaStar Medical Holding Corporation approved a 1-for-10 reverse stock split of its common stock. Every 10 existing shares will be automatically combined into one new share.

When does SeaStar Medical's 1-for-10 reverse stock split take effect?

The reverse stock split will be effective as of 12:01 a.m. Eastern Standard Time on January 2, 2026. The common stock will begin trading on a split-adjusted basis on that date.

How many SeaStar Medical (ICU) shares will be outstanding after the reverse split?

Immediately after the reverse split becomes effective, there will be approximately 3.8 million shares of SeaStar Medical common stock issued and outstanding.

How will SeaStar Medical handle fractional shares in the reverse split?

The company will not issue fractional shares. Any fractional share amounts will be rounded up to the next whole share for affected stockholders.

What happens to SeaStar Medical stock options and warrants in the reverse split?

All stock options and warrants outstanding immediately prior to the reverse split will be proportionally adjusted so their value and terms reflect the 1-for-10 split.

Did SeaStar Medical (ICU) change its authorized share count?

Yes. Stockholders approved an amendment to reduce the number of authorized common shares by 25,000,000, resulting in a new authorized total of 425,000,000 common shares.

Do SeaStar Medical shareholders need to take action for the reverse split?

Stockholders holding shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the reverse split, subject to their broker's processes, and generally are not required to take further action.

SeaStar Medical Holding Corp

NASDAQ:ICU

ICU Rankings

ICU Latest News

ICU Latest SEC Filings

ICU Stock Data

9.27M
35.76M
0.95%
6.98%
11.21%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States
DENVER